A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions
Cancers · 05.01.2025 · 17 (1) · 147
DOI: 10.3390/cancers17010147 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.01.2025. Verfasst von Parissa Alerasool und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Oligometastatic prostate cancer (OMPC) represents an intermediate state in the progression from localized disease to widespread metastasis when the radiographically significant sites are limited in number and location. With no clear consensus on a definition, its diagnostic significance and associated optimal therapeutic approach remain controversial, posing a significant challenge for clinicians. The current standard of care for metastatic disease is to start systemic therapy; however, active surveillance and targeted radiotherapy have become attractive options to mitigate the long-term effects of androgen deprivation therapy (ADT). Furthermore, evolving biomarker methodologies may further define optimal treatment selection. In this review, we summarize the current understanding that guides the treatment of OMPC, with a focus on how host response can be an important contributing factor. Evolving scientific understanding and clinical development will continue to shape the landscape of treatment strategies for this distinct disease state.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Medicine, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY 10467, USA.
- Department of Medicine, Icahn School of Medicine at Mount Sinai (Morningside/West), New York, NY 10025, USA.
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
ORCID-Profile: Natasha Kyprianou
Förderung
- NCI NIH HHS
Zitieren
APA
Alerasool, P., Zhou, S., Miller, E., Anker, J., Tsao, B., Kyprianou, N., & Tsao, C. K. (2025). A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions. Cancers, 17(1), 147. https://doi.org/10.3390/cancers17010147
Vancouver
Alerasool P, Zhou S, Miller E, Anker J, Tsao B, Kyprianou N, et al. A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions. Cancers. 2025;17(1):147. doi:10.3390/cancers17010147
BibTeX
@article{Alerasool2025,
author = {Alerasool, Parissa and Zhou, Susu and Miller, Eric and Anker, Jonathan and Tsao, Brandon and Kyprianou, Natasha and Tsao, Che-Kai},
title = {A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions},
journal = {Cancers},
year = {2025},
volume = {17},
number = {1},
pages = {147},
doi = {10.3390/cancers17010147}
}
EUVIMED